A recent study published in the journal JAMA revealed a staggering 594.4% increase in the number of prescriptions for GLP-1 agonist drugs among young individuals aged 12 to 25 in the United States between 2020 and 2023. These medications, such as Wegovy and Ozempic, are commonly used for weight loss and managing type 2 diabetes.
The study highlighted that young women and adolescent girls showed the most significant rise in prescription rates for these drugs. The data, sourced from a comprehensive pharmacy database, indicated a substantial shift towards prescribing GLP-1 agonists in this age group.
